Bio-Techne sells the reagents, antibodies, and instruments that life-science labs use to study cells and proteins—think of it as a specialty tool-and-supply shop for researchers and diagnostic makers.
Money comes from recurring sales of consumables like antibodies, assays, and controls, plus instruments; gross margins run around 66%, with net margin near 15% on USD 1.22B in annual revenue, though it dipped to 6% last year.
Deep catalog of validated biological reagents that labs rely on for reproducibility, hard to replicate quickly; competitors like Thermo Fisher and Abcam offer alternatives, but switching costs are high. Moat is solid but faces slow erosion from commoditization
Hold (sector percentile 64) — value C+, growth A, profitability B, momentum B, revisions C-. Updated daily, sector-relative, identical for every user.
Key events, in time order
Q4 results covered by multiple sources; diagnostics and spatial biology grow; Merck deal in focus
Institutional holding change reflects long-term capital allocation shift
Institutional buying coincides with new high, indicating positive sentiment.
$73/sh cash, ~20% premium, pre-market +19.9%
Per Bloomberg, Ananym Capital holds stake and pushes for strategic review including sale; shares +2.6% premarket
None yet
None yet
Unusual call option volume is increasing for $TECH, indicating potential bullish sentiment or speculative activity. The discussion is driven by options market signals.
Main discussion
Increasing unusual call option volume: $KC $TECH $AS $ARKG $VUZI $HBAN $NXE $MUU $VIST $CTSH
$MRNA is up almost 100% today Now its personalized cancer vaccine with Merck has succeeded in a Phase 3 melanoma trial. Genomics is quietly coming back to life Full research and ecosystem map: http://10xdisruptivestocks.substack.com/p/best-genomics-stocks Genomics Ecosystem: • DN
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
